Literature DB >> 3657811

Antibodies to synthetic peptides from the pre-S1 and pre-S2 regions of one subtype of the hepatitis B virus (HBV) envelope protein recognize all HBV subtypes.

A R Neurath1, S B Kent, N Strick, K Parker, A M Courouce, M M Riottot, M A Petit, A Budkowska, M Girard, J Pillot.   

Abstract

Immunodominant B and T cell epitopes have been demonstrated recently on the preS1 and PreS2 regions of the hepatitis B virus (HBV) envelope protein. Synthetic peptide analogs corresponding to the preS2 region elicit virus-neutralizing antibodies and protect chimpanzees against HBV infection. Antibodies raised by immunization with peptides derived from the preS1 sequence block the site involved in HBV attachment to cell receptors, and are expected to be virus-neutralizing. Results presented here show that antisera raised against synthetic peptide analogs carrying the immunodominant epitope of the preS1 and preS2 sequence, respectively, and corresponding to two HBV subtypes, adw2 and ayw, each recognized preS1 and preS2 specific epitopes on all serological subtypes of the HBV envelope protein. Thus, the sequence variability within the preS1 and preS2 regions does not represent an impediment to the development of synthetic peptide or genetically engineered hepatitis B preS immunogens for worldwide immunization.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3657811     DOI: 10.1016/0161-5890(87)90009-5

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  4 in total

1.  Immunization with a peptide corresponding to chlamydial heat shock protein 60 increases the humoral immune response in C3H mice to a peptide representing variable domain 4 of the major outer membrane protein of Chlamydia trachomatis.

Authors:  V L Motin; L M de la Maza; E M Peterson
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice.

Authors:  Eberhard Hildt; Barbara Munz; Gesine Saher; Kurt Reifenberg; Peter Hans Hofschneider
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

3.  Epitope mapping of neutralizing monoclonal antibodies against duck hepatitis B virus.

Authors:  R C Cheung; W S Robinson; P L Marion; H B Greenberg
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

4.  Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.

Authors:  D C Whitacre; C J Peters; C Sureau; K Nio; F Li; L Su; J E Jones; M Isogawa; M Sallberg; L Frelin; D L Peterson; D R Milich
Journal:  Hum Vaccin Immunother       Date:  2019-12-06       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.